Business Wire

AVALON-CAPITAL-PARTNERS

Share
Avalon Adds Five Senior Hires to Event Driven and International Equities Teams

Avalon Capital Partners Limited (“Avalon”) has hired five senior cash equity salespeople as it continues with rapid expansion plans across both Event Driven and International Equities.

In the Event Driven division, Aaron Sawyer, Holger Klees and Gregory Lafitte have joined the team to bolster Avalon’s already considerable presence in this market.

In the International Equities Division, Conor Smith and Gavin Atkins join from Cantor Fitzgerald to lead the build out of an institutional cash equity desk, providing liquidity to an international client base.

“The continued expansion of Avalon with these hires is demonstration of our commitment to the Equity space. Where others are pulling out of equities, we are expanding. There is increasing investment in European equity and we have sales, research and trading teams ready to assist our clients in maximizing their returns,” said Jean-Yves Aknin, Avalon’s CEO.

“We are delighted to add Aaron, Holger, Gregory, Conor and Gavin to Avalon. Their track record and commitment to offering the best service to institutional customers is impressive and we look forward to their contribution to our success,” added Simon Langford, Avalon’s Managing Director.

Aaron Sawyer has over 20 years’ industry experience with resultant deep-seated market and multiple economic cycle expertise. Aaron has a strong background in Equity Finance, Special Situations, ECM and Long/Short alpha strategies. Before joining Avalon, Aaron spent ten years at Credit Suisse before joining Jefferies and then Macquarie to team-up with Holger on the build out of their European operations.

Holger Klees is a specialist in Event Driven with over 20 years’ experience. Prior to joining Avalon, Holger worked for Macquarie Bank and was part of Jefferies International’s European build out. He previously worked for Pali Capital and Lehman Brothers. Holger started his career in Derivatives Sales at BHF Bank where he set up a German focused arbitrage desk.

Gregory Lafitte brings sixteen years of expertise as a portfolio manager. He has covered a variety of markets but has a focus on US and Asian special situations. Gregory started his career at CM-CIC Market where he set up and developed the Asian merger arbitrage proprietary desk. He later relocated to Europe, joining Bred Banque Populaire in 2011, where he oversaw both the US and Asian merger arbitrage proprietary trading. Since then, Gregory has held roles Opera Trading and Makor Group.

Conor Smith brings 20 years of International Equities experience with extensive knowledge of equity analysis, market making, proprietary trading and sales. He has held roles at HSBC, Man Group, MF Global and Cantor Fitzgerald.

Gavin Atkins is an industry veteran who has spent 22 years in International Equities at Cantor Fitzgerald. Prior to that, Gavin held roles at Bishop Fleming and UBS.

About Avalon Capital Partners

One of the fastest growing brokerage firms in London, Avalon is an institutional broker providing extensive market knowledge and a dedication for providing a first-class service to a global institutional client base. At Avalon, client needs are our primary focus. We guarantee an unparalleled customer service from our dedicated and experienced teams, providing access to global markets and state-of-the-art technology.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release

Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye